Abstract:Protease activated receptor 4 (PAR4) is an important target in antiplatelet therapy to reduce the risk of heart attack and thrombotic complications in stroke. PAR4 antagonists can prevent harmful and stable thrombus growth, while retaining initial thrombus formation, by acting on the late diffusion stage of platelet aggregation, and may provide a safer alternative to other antiplatelet agents. To date, only two PAR4 antagonists, BMS-986120 and BMS-986141 have entered clinical trials for thrombosis. Thus, the development of a potent and selective PAR4 antagonist with a novel chemotype is highly desirable. In this study, we explored the activity of quinazolin-4(3H)-one-based PAR4 antagonists, beginning with their IDT analogues. By repeated structural optimisation, we developed a series of highly selective PAR4 antagonists with nanomolar potency on human platelets. Of these, 13 and 30g, with an 8-benzo[d]thiazol-2-yl-substituted quinazolin-4(3H)-one structure, showed optimal activity (h. PAR4-AP PRP IC50 = 19.6 nM and 6.59 nM, respectively) on human platelets. Furthermore, 13 and 30g showed excellent selectivity for PAR4 versus PAR1 and other receptors (IC50s > 10 μM) on human platelets. And 13 and 30g were lack of cross-reactivity for PAR1 or PAR2 (PAR1 AP FLIPR IC50 > 3162 nM, PAR2 AP FLIPR IC50 > 1000 nM) in the calcium mobilization assays. Metabolic stability assays and cytotoxicity tests of 13 and 30g indicated that these compounds could sever as promising drug candidates for the development of novel PAR4 antagonists. In summary, the quinazolin-4(3H)-one-based analogues are the first reported chemotypes with excellent activity and selectivity against PAR4, and, in the current study, we expanded the structural diversity of PAR4 antagonists. The two compounds, 13 and 30g, found in our study could be promising starting points with great potential for further research in antiplatelet therapy.

Research progress on thrombin receptorantagonists

Protease activated receptor 4 (PAR4) antagonists: Research progress on small molecules in the field of antiplatelet agents

[Roles of Protease-Activated Receptor-1 in Thrombin-Induced Brain Injury and Neurogenesis in Rats].

New Medicine for Antithrombotic Treatment of Atrial Fibrillation—Who Can Dominate in the Future

Inhibitors of protease-activated receptor 4 (PAR4): a review of recent patents (2013-2021)

Inhibitors of Protease-Activated Receptor 4 (PAR4): a Review of Recent Patents (2013-2021).

Research Progress on Thrombin Inhibitor

Discovery of quinazoline-benzothiazole derivatives as novel potent protease-activated receptor 4 antagonists with improved pharmacokinetics and low bleeding liability

Synthesis and Evaluation of Novel and Potent Protease Activated Receptor 4 (PAR4) Antagonists Based on a Quinazolin-4(3H)-one Scaffold.

Discovery of Potent Orally Active Protease-Activated Receptor 1 (par1) Antagonists Based on Andrographolide

Discovery of Potent and Selective Quinoxaline-Based Protease-Activated Receptor 4 (PAR4) Antagonists for the Prevention of Arterial Thrombosis

Therapeutic Potential of Targeting Protease Activated Receptors in Cardiovascular Diseases

Advances in Inhibitors of Fxa

Protease-Activated Receptor 4 (PAR4): A Promising Target for Antiplatelet Therapy

Advances in Research of ADP Receptors and Antagonists of Platelets

Discovery of 7, 4-dimethoxy-3-hydroxyflavone as a protease-activated receptor 4 antagonist with antithrombotic activity and less bleeding tendency in mice

Progress in research of P2Y12 receptor antagonists antiplatelet drugs

Novel Agents for Anti-Platelet Therapy

Thrombolysis of plasmin and its derivatives:research advances

PAR1 Inhibition Vorapaxar as a Potential Therapeutic Approach in Chronic Thromboembolic Pulmonary Hypertension

Progress in the development of antiplatelet agents: Focus on the targeted molecular pathway from bench to clinic